Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale grew its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 26.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 51,997 shares of the biopharmaceutical company’s stock after acquiring an additional 11,000 shares during the period. DekaBank Deutsche Girozentrale owned about 0.05% of Intra-Cellular Therapies worth $3,791,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Lazard Asset Management LLC purchased a new stake in shares of Intra-Cellular Therapies in the 2nd quarter valued at approximately $29,000. Neo Ivy Capital Management purchased a new stake in shares of Intra-Cellular Therapies in the 3rd quarter valued at approximately $45,000. Coppell Advisory Solutions Corp. purchased a new stake in shares of Intra-Cellular Therapies in the 4th quarter valued at approximately $47,000. International Assets Investment Management LLC purchased a new stake in shares of Intra-Cellular Therapies in the 4th quarter valued at approximately $51,000. Finally, State of Wyoming raised its stake in shares of Intra-Cellular Therapies by 57.9% in the 2nd quarter. State of Wyoming now owns 851 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 312 shares during the period. 92.33% of the stock is owned by hedge funds and other institutional investors.

Intra-Cellular Therapies Price Performance

Shares of NASDAQ:ITCI opened at $65.88 on Friday. The stock has a market cap of $6.38 billion, a P/E ratio of -45.12 and a beta of 1.02. The firm has a fifty day moving average price of $69.03 and a 200 day moving average price of $63.32. Intra-Cellular Therapies, Inc. has a 1-year low of $45.50 and a 1-year high of $76.11.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.14. Intra-Cellular Therapies had a negative net margin of 30.08% and a negative return on equity of 23.02%. The company had revenue of $132.10 million during the quarter, compared to analysts’ expectations of $135.97 million. During the same quarter last year, the business earned ($0.45) EPS. The business’s revenue was up 50.3% on a year-over-year basis. Sell-side analysts expect that Intra-Cellular Therapies, Inc. will post -0.65 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ITCI shares. Bank of America upped their target price on shares of Intra-Cellular Therapies from $74.00 to $82.00 and gave the stock a “buy” rating in a research note on Tuesday, January 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $101.00 target price on shares of Intra-Cellular Therapies in a research note on Friday, February 23rd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $86.00 target price on shares of Intra-Cellular Therapies in a research note on Wednesday, April 3rd. Robert W. Baird started coverage on shares of Intra-Cellular Therapies in a research note on Wednesday, January 3rd. They set an “outperform” rating and a $83.00 target price on the stock. Finally, Canaccord Genuity Group cut their target price on shares of Intra-Cellular Therapies from $101.00 to $100.00 and set a “buy” rating on the stock in a research note on Friday, February 23rd. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $81.42.

Insider Transactions at Intra-Cellular Therapies

In other news, EVP Suresh K. Durgam sold 6,450 shares of the firm’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $66.56, for a total value of $429,312.00. Following the completion of the sale, the executive vice president now owns 16,170 shares in the company, valued at approximately $1,076,275.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Sharon Mates sold 67,917 shares of the firm’s stock in a transaction on Thursday, January 18th. The shares were sold at an average price of $65.19, for a total value of $4,427,509.23. Following the completion of the sale, the chief executive officer now owns 1,050,309 shares in the company, valued at approximately $68,469,643.71. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Suresh K. Durgam sold 6,450 shares of the firm’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $66.56, for a total transaction of $429,312.00. Following the completion of the sale, the executive vice president now owns 16,170 shares of the company’s stock, valued at approximately $1,076,275.20. The disclosure for this sale can be found here. In the last quarter, insiders sold 311,765 shares of company stock worth $20,860,487. Company insiders own 3.40% of the company’s stock.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.